Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease
Identifieur interne : 000C55 ( Ncbi/Merge ); précédent : 000C54; suivant : 000C56Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease
Auteurs : Debendra Pattanaik ; Sandeep Gupta ; Syed Islam ; Kunal Singhal ; Syed RazaSource :
- Acr Open Rheumatology [ 2578-5745 ] ; 2019.
Abstract
The optimal strategy to detect the development of tuberculosis
This is a retrospective study among veteran populations with rheumatic diseases who received various biologic agents between 2003 and 2014. Subjects who had repeated TB screening tests and adequate follow‐up periods were considered for the study.
Out of 298 subjects who received biologic agents, 123 were considered for the study. After the initial negative screening test by tuberculin skin test (TST), patients were screened on an average of 1.2 years for 4.3 to 12 years. A total of 420 tests were performed, which were combination of TST and QuantiFERON‐TB gold in‐Tube assay. Only 1 out of 123 subjects (0.8%) seroconverted to latent TB and was treated with isoniazid for 9 months.
Our results are in line with a few other studies reported from the United States. We conclude that in areas with low prevalence of TB the seroconversion rate is extremely low and annual testing is unnecessary in low‐risk patient populations.
Url:
DOI: 10.1002/acr2.11070
PubMed: 31777837
PubMed Central: 6857984
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000264
- to stream Pmc, to step Curation: 000264
- to stream Pmc, to step Checkpoint: 000869
Links to Exploration step
PMC:6857984Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease</title><author><name sortKey="Pattanaik, Debendra" sort="Pattanaik, Debendra" uniqKey="Pattanaik D" first="Debendra" last="Pattanaik">Debendra Pattanaik</name><affiliation><nlm:aff id="acr211070-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Gupta, Sandeep" sort="Gupta, Sandeep" uniqKey="Gupta S" first="Sandeep" last="Gupta">Sandeep Gupta</name><affiliation><nlm:aff id="acr211070-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Islam, Syed" sort="Islam, Syed" uniqKey="Islam S" first="Syed" last="Islam">Syed Islam</name><affiliation><nlm:aff id="acr211070-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Singhal, Kunal" sort="Singhal, Kunal" uniqKey="Singhal K" first="Kunal" last="Singhal">Kunal Singhal</name><affiliation><nlm:aff id="acr211070-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Raza, Syed" sort="Raza, Syed" uniqKey="Raza S" first="Syed" last="Raza">Syed Raza</name><affiliation><nlm:aff id="acr211070-aff-0001"></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31777837</idno><idno type="pmc">6857984</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857984</idno><idno type="RBID">PMC:6857984</idno><idno type="doi">10.1002/acr2.11070</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000264</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000264</idno><idno type="wicri:Area/Pmc/Curation">000264</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000264</idno><idno type="wicri:Area/Pmc/Checkpoint">000869</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000869</idno><idno type="wicri:Area/Ncbi/Merge">000C55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease</title><author><name sortKey="Pattanaik, Debendra" sort="Pattanaik, Debendra" uniqKey="Pattanaik D" first="Debendra" last="Pattanaik">Debendra Pattanaik</name><affiliation><nlm:aff id="acr211070-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Gupta, Sandeep" sort="Gupta, Sandeep" uniqKey="Gupta S" first="Sandeep" last="Gupta">Sandeep Gupta</name><affiliation><nlm:aff id="acr211070-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Islam, Syed" sort="Islam, Syed" uniqKey="Islam S" first="Syed" last="Islam">Syed Islam</name><affiliation><nlm:aff id="acr211070-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Singhal, Kunal" sort="Singhal, Kunal" uniqKey="Singhal K" first="Kunal" last="Singhal">Kunal Singhal</name><affiliation><nlm:aff id="acr211070-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Raza, Syed" sort="Raza, Syed" uniqKey="Raza S" first="Syed" last="Raza">Syed Raza</name><affiliation><nlm:aff id="acr211070-aff-0001"></nlm:aff></affiliation></author></analytic><series><title level="j">Acr Open Rheumatology</title><idno type="eISSN">2578-5745</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="acr211070-sec-0001"><title>Objective</title><p>The optimal strategy to detect the development of tuberculosis <bold>(</bold>TB) in subjects receiving biologic agents is not clear. The recommendations vary because there is wide variation in the reported rate of seroconversion in various parts of the world. There is a scarcity of long‐term studies regarding seroconversion of TB in the United States among these patients.</p></sec><sec id="acr211070-sec-0002"><title>Methods</title><p>This is a retrospective study among veteran populations with rheumatic diseases who received various biologic agents between 2003 and 2014. Subjects who had repeated TB screening tests and adequate follow‐up periods were considered for the study.</p></sec><sec id="acr211070-sec-0003"><title>Results</title><p>Out of 298 subjects who received biologic agents, 123 were considered for the study. After the initial negative screening test by tuberculin skin test (TST), patients were screened on an average of 1.2 years for 4.3 to 12 years. A total of 420 tests were performed, which were combination of TST and QuantiFERON‐TB gold in‐Tube assay. Only 1 out of 123 subjects (0.8%) seroconverted to latent TB and was treated with isoniazid for 9 months.</p></sec><sec id="acr211070-sec-0004"><title>Conclusion</title><p>Our results are in line with a few other studies reported from the United States. We conclude that in areas with low prevalence of TB the seroconversion rate is extremely low and annual testing is unnecessary in low‐risk patient populations.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="brief-report"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">ACR Open Rheumatol</journal-id><journal-id journal-id-type="iso-abbrev">ACR Open Rheumatol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2578-5745</journal-id><journal-id journal-id-type="publisher-id">ACR2</journal-id><journal-title-group><journal-title>Acr Open Rheumatology</journal-title></journal-title-group><issn pub-type="epub">2578-5745</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31777837</article-id><article-id pub-id-type="pmc">6857984</article-id><article-id pub-id-type="doi">10.1002/acr2.11070</article-id><article-id pub-id-type="publisher-id">ACR211070</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title>Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease</article-title><alt-title alt-title-type="right-running-head">SEROCONVERSION OF TB DURING BIOLOGIC THERAPY</alt-title><alt-title alt-title-type="left-running-head">PATTANAIK ET AL</alt-title></title-group><contrib-group><contrib id="acr211070-cr-0001" contrib-type="author" corresp="yes"><name><surname>Pattanaik</surname><given-names>Debendra</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5751-7022</contrib-id><xref ref-type="aff" rid="acr211070-aff-0001"><sup>1</sup></xref><address><email>dpattana@uthsc.edu</email></address></contrib><contrib id="acr211070-cr-0002" contrib-type="author"><name><surname>Gupta</surname><given-names>Sandeep</given-names></name><xref ref-type="aff" rid="acr211070-aff-0001"><sup>1</sup></xref></contrib><contrib id="acr211070-cr-0003" contrib-type="author"><name><surname>Islam</surname><given-names>Syed</given-names></name><xref ref-type="aff" rid="acr211070-aff-0001"><sup>1</sup></xref></contrib><contrib id="acr211070-cr-0004" contrib-type="author"><name><surname>Singhal</surname><given-names>Kunal</given-names></name><xref ref-type="aff" rid="acr211070-aff-0001"><sup>1</sup></xref></contrib><contrib id="acr211070-cr-0005" contrib-type="author"><name><surname>Raza</surname><given-names>Syed</given-names></name><xref ref-type="aff" rid="acr211070-aff-0001"><sup>1</sup></xref></contrib></contrib-group><aff id="acr211070-aff-0001"><label><sup>1</sup></label><institution>University of Tennessee Health Science Center</institution><city>Memphis</city><named-content content-type="country-part">Tennessee</named-content></aff><author-notes><corresp id="correspondenceTo"><label>*</label>Address correspondence to Debendra Pattanaik, MD, Division of Rheumatology, University of Tennessee Health Science Center, Veterans Affairs Medical Center, 956 Court Avenue, Room G326, Memphis, TN 38163. E‐mail: <email>dpattana@uthsc.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>8</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2019</year></pub-date><volume>1</volume><issue>9</issue><issue-id pub-id-type="doi">10.1002/acr2.v1.9</issue-id><fpage>542</fpage><lpage>545</lpage><history><date date-type="received"><day>31</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>16</day><month>7</month><year>2019</year></date></history><permissions><pmc-comment> © 2019 American College of Rheumatology </pmc-comment>
<copyright-statement content-type="article-copyright">© 2019 The Authors. <italic>ACR Open Rheumatology</italic> published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:ACR2-1-542.pdf"></self-uri><abstract id="acr211070-abs-0001"><sec id="acr211070-sec-0001"><title>Objective</title><p>The optimal strategy to detect the development of tuberculosis <bold>(</bold>TB) in subjects receiving biologic agents is not clear. The recommendations vary because there is wide variation in the reported rate of seroconversion in various parts of the world. There is a scarcity of long‐term studies regarding seroconversion of TB in the United States among these patients.</p></sec><sec id="acr211070-sec-0002"><title>Methods</title><p>This is a retrospective study among veteran populations with rheumatic diseases who received various biologic agents between 2003 and 2014. Subjects who had repeated TB screening tests and adequate follow‐up periods were considered for the study.</p></sec><sec id="acr211070-sec-0003"><title>Results</title><p>Out of 298 subjects who received biologic agents, 123 were considered for the study. After the initial negative screening test by tuberculin skin test (TST), patients were screened on an average of 1.2 years for 4.3 to 12 years. A total of 420 tests were performed, which were combination of TST and QuantiFERON‐TB gold in‐Tube assay. Only 1 out of 123 subjects (0.8%) seroconverted to latent TB and was treated with isoniazid for 9 months.</p></sec><sec id="acr211070-sec-0004"><title>Conclusion</title><p>Our results are in line with a few other studies reported from the United States. We conclude that in areas with low prevalence of TB the seroconversion rate is extremely low and annual testing is unnecessary in low‐risk patient populations.</p></sec></abstract><counts><fig-count count="0"></fig-count><table-count count="4"></table-count><page-count count="4"></page-count><word-count count="3089"></word-count></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.2 mode:remove_FC converted:15.11.2019</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="acr211070-ntgp-0001"><fn id="acr211070-note-0002"><p>No potential conflicts of interest relevant to this article were reported.</p></fn></fn-group></notes></front></pmc><affiliations><list></list><tree><noCountry><name sortKey="Gupta, Sandeep" sort="Gupta, Sandeep" uniqKey="Gupta S" first="Sandeep" last="Gupta">Sandeep Gupta</name><name sortKey="Islam, Syed" sort="Islam, Syed" uniqKey="Islam S" first="Syed" last="Islam">Syed Islam</name><name sortKey="Pattanaik, Debendra" sort="Pattanaik, Debendra" uniqKey="Pattanaik D" first="Debendra" last="Pattanaik">Debendra Pattanaik</name><name sortKey="Raza, Syed" sort="Raza, Syed" uniqKey="Raza S" first="Syed" last="Raza">Syed Raza</name><name sortKey="Singhal, Kunal" sort="Singhal, Kunal" uniqKey="Singhal K" first="Kunal" last="Singhal">Kunal Singhal</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000C55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:6857984
|texte= Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:31777837" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |